Working... Menu

Preterm Delivery Prevention in Twins With Progesterone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01927029
Recruitment Status : Unknown
Verified August 2013 by Masami Yamamoto, Clinica Alemana de Santiago.
Recruitment status was:  Active, not recruiting
First Posted : August 21, 2013
Last Update Posted : August 21, 2013
Hospital Padre Hurtado
Hospital San Borja-Arriaran
Information provided by (Responsible Party):
Masami Yamamoto, Clinica Alemana de Santiago

Brief Summary:
Twin pregnancies have very high preterm delivery rate. Until now, no RCT has proven benefit of progesterone in this population. In contrast, singleton pregnancies are treated with this hormone. The objective is to compare 180mg/day progeterone vaginal gel with 180mg/day with placebo, from 18 weeks to 34 weeks. The sample size was calculated and 213 cases in each group are needed to demonstrate a reduction of preterm delivery <34weeks from 13% to 7%.

Condition or disease Intervention/treatment Phase
Pregnancies Drug: Progesterone Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 213 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal.
Study Start Date : August 2013
Estimated Primary Completion Date : October 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Progesterone
Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
Drug: Progesterone
Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
Other Name: Progendo gel

Placebo Comparator: Placebo
Placebo Gel, for daily use from 18 weeks to 34 weeks.
Drug: Placebo

Primary Outcome Measures :
  1. Preterm delivery <34 weeks [ Time Frame: 14 months ]
    Spontaneous labor under 34 weeks.

Secondary Outcome Measures :
  1. Preterm delivery <37 weeks [ Time Frame: 14 months ]
    Spontaneous delivery under 37 weeks

Other Outcome Measures:
  1. Neonatal mortality [ Time Frame: 14 months ]
    Dead of the newborn, due to preterm delivery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Monochorionic or Dichorionic twin pregnancies
  • 18 weeks to 24 weeks at inclusion.

Exclusion Criteria:

  • Cerclage before inclusion
  • Contractions, rupture of the membranes, cervix dilation,
  • Short cervix (15mm or 20mm if there is history of preterm delivery
  • Monoamniotic twins, Major malformation, Selective IUGR, TRAP, TTTS.
  • Younger than 14 years.

Layout table for additonal information
Responsible Party: Masami Yamamoto, MD, Clinica Alemana de Santiago Identifier: NCT01927029     History of Changes
Other Study ID Numbers: CAS149
First Posted: August 21, 2013    Key Record Dates
Last Update Posted: August 21, 2013
Last Verified: August 2013

Keywords provided by Masami Yamamoto, Clinica Alemana de Santiago:
twin pregnancy
preterm delivery
>14 years
Abscense of cerclage,
TTTS, hemorrage,
history of thrombosis.
cervix >15mm

Additional relevant MeSH terms:
Layout table for MeSH terms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs